IMMUTEP Ltd
For the period ended Aug 31, 2026. Filed Sep 2, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Aug 31, 2026 · Filed Sep 2, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · 23. EQUITY – CONTRIBUTED (CONTINUED)
23. EQUITY – CONTRIBUTED (CONTINUED)
Options
Information relating to the Company’s Executive Incentive Plan, including details of options issued, exercised and lapsed during the financial year and options outstanding at the end of the reporting period, is set out in note 35.
Unlisted options
There were no unlisted options on issue as at 30 June 2026. The balance as at 30 June 2025 is set out in the table below.
| Expiration Date | Exercise Price | Number |
|---|---|---|
| 4 August 2025 | $0.24 | 847,600 |
*Sharebuy-back *
There is no currenton-market sharebuy-back.
Capital risk management
The consolidated entity’s objectives when managing capital are to safeguard its ability to continue as a going concern, so that the entity can continue to pursue its clinical program to grow the entity’s underlying value and maintain an optimal capital structure to reduce the cost of capital.
In order to maintain or adjust the capital structure, the consolidated entity may return capital to shareholders, and or issue new shares.
The consolidated entity would look to raise capital when an opportunity to invest in a business or company was seen as value adding relative to the current parent entity’s share price at the time of the investment. The consolidated entity is not actively pursuing additional investments in the short term as it continues to grow its existing business.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.